Biohaven - BHVN Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
News Sentiment
About
FAQ

Consensus Rating: Buy
Consensus Price Target: $52.13
Forecasted Upside: 33.76%
Number of Analysts: 8
Breakdown:
0 Sell Ratings
0 Hold Ratings
8 Buy Ratings
0 Strong Buy Ratings

^$38.97 As of 04/26/2024 01:00 AM ET

▲ +0.43 (1.12%)

1 month | 3 months | 12 months

Get New Biohaven Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for BHVN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BHVN

^$52.13

▲ +33.76% Upside Potential

This price target is based on 8 analysts offering 12 month price targets for Biohaven in the last 3 months. The average price target is $52.13, with a high forecast of $63.00 and a low forecast of $28.00. The average price target represents a 33.76% upside from the last price of $38.97.

Current Consensus is Buy

The current consensus among 8 contributing investment analysts is to buy stock in Biohaven. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
8 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

11/5/2022

0 strong buy ratings
8 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

2/3/2023

0 strong buy ratings
8 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

5/4/2023

0 strong buy ratings
8 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

8/2/2023

0 strong buy ratings
8 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

10/31/2023

0 strong buy ratings
8 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

1/29/2024

0 strong buy ratings
8 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

3/29/2024

0 strong buy ratings
8 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

4/28/2024

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
4/23/2024	UBS Group	Boost Target	Buy ➝ Buy	$59.00 ➝ $60.00	Low
4/18/2024	Cantor Fitzgerald	Reiterated Rating	Overweight		Low
4/10/2024	Cantor Fitzgerald	Reiterated Rating	Overweight		Low
4/9/2024	Royal Bank of Canada	Reiterated Rating	Outperform ➝ Outperform	$61.00	Low
3/4/2024	HC Wainwright	Boost Target	Buy ➝ Buy	$50.00 ➝ $63.00	Low
3/1/2024	Royal Bank of Canada	Lower Target	Outperform ➝ Outperform	$62.00 ➝ $61.00	Low
3/1/2024	TD Cowen	Boost Target	Outperform ➝ Outperform	$35.00 ➝ $55.00	Low
2/23/2024	JPMorgan Chase & Co.	Boost Target	Overweight ➝ Overweight	$32.00 ➝ $56.00	Low
2/16/2024	Royal Bank of Canada	Initiated Coverage	Outperform	$62.00	Low
2/6/2024	UBS Group	Initiated Coverage	Buy	$59.00	Low
12/22/2023	HC Wainwright	Initiated Coverage	Buy	$50.00	Low
12/8/2023	Robert W. Baird	Initiated Coverage	Outperform	$58.00	Low
11/20/2023	JPMorgan Chase & Co.	Boost Target	Overweight ➝ Overweight	$26.00 ➝ $32.00	Low
11/15/2023	Piper Sandler	Boost Target	Overweight ➝ Overweight	$29.00 ➝ $36.00	Low
8/16/2023	JPMorgan Chase & Co.	Lower Target	Overweight ➝ Overweight	$27.00 ➝ $24.00	Low
6/5/2023	BTIG Research	Boost Target		$24.00 ➝ $28.00	Low
4/4/2023	Cantor Fitzgerald	Boost Target	Overweight	$27.00 ➝ $31.00	Low
1/24/2023	SVB Leerink	Reiterated Rating	Outperform	$24.00	Low
1/24/2023	SVB Securities	Initiated Coverage	Outperform	$24.00	Low
1/4/2023	JPMorgan Chase & Co.	Initiated Coverage	Overweight	$23.00	Low
12/2/2022	BTIG Research	Initiated Coverage	Buy	$24.00	Low
11/7/2022	Cowen	Set Target		$25.00	Low
11/7/2022	Cowen	Lower Target		$25.00	Low
10/26/2022	Cantor Fitzgerald	Upgrade	Neutral ➝ Overweight	$158.00 ➝ $27.00	Low
10/26/2022	Piper Sandler	Lower Target	Overweight	$23.00 ➝ $21.00	Low
10/12/2022	Piper Sandler	Initiated Coverage	Overweight	$23.00	Low
8/18/2022	Piper Sandler	Downgrade	Overweight ➝ Neutral	$149.00	Low
8/8/2022	Wedbush	Downgrade	Outperform ➝ Neutral	$148.50	Low
5/24/2022	Piper Sandler	Lower Target	NA	$156.00 ➝ $149.00	Low
5/11/2022	Cantor Fitzgerald	Downgrade	Overweight ➝ Neutral		Low
5/11/2022	HC Wainwright	Downgrade	Buy ➝ Neutral		Low
5/11/2022	SVB Leerink	Downgrade	Outperform ➝ Market Perform	$150.00	Low
4/6/2022	Morgan Stanley	Lower Target	Equal Weight	$148.00 ➝ $146.00	High
3/3/2022	Mizuho	Boost Target	Buy	$144.00 ➝ $154.00	Low
1/7/2022	HC Wainwright	Reiterated Rating	Buy	$160.00	High
1/7/2022	Morgan Stanley	Boost Target	Equal Weight	$145.00 ➝ $148.00	Medium
1/4/2022	UBS Group	Boost Target		$150.00 ➝ $160.00	High
12/7/2021	HC Wainwright	Reiterated Rating	Buy	$160.00	Low
11/18/2021	Mizuho	Boost Target	Positive ➝ Buy	$135.00 ➝ $144.00	Medium
11/10/2021	Cantor Fitzgerald	Boost Target	Overweight	$165.00 ➝ $177.00	Medium
11/10/2021	Mizuho	Lower Target	Buy	$137.00 ➝ $135.00	Medium
10/19/2021	Morgan Stanley	Boost Target	Equal Weight	$107.00 ➝ $145.00	Low
10/7/2021	SVB Leerink	Reiterated Rating	Buy		Low
10/6/2021	HC Wainwright	Reiterated Rating	Buy	$135.00 ➝ $160.00	Low
10/6/2021	The Goldman Sachs Group	Boost Target	Buy	$151.00 ➝ $170.00	Low
10/5/2021	Mizuho	Reiterated Rating	Buy	$137.00	Low
10/5/2021	Piper Sandler	Boost Target	Overweight	$140.00 ➝ $156.00	Medium
9/13/2021	Cantor Fitzgerald	Boost Target	Overweight	$151.00 ➝ $165.00	High
8/10/2021	UBS Group	Downgrade	Buy ➝ Neutral	$108.00 ➝ $109.00	High
7/16/2021	Morgan Stanley	Boost Target	Equal Weight	$69.00 ➝ $107.00	High
7/12/2021	Mizuho	Boost Target	Buy	$92.00 ➝ $134.00	Low
7/8/2021	HC Wainwright	Boost Target	Buy	$111.00 ➝ $135.00	High
7/7/2021	Cowen	Boost Target	Outperform	$90.00 ➝ $130.00	High
6/1/2021	Cantor Fitzgerald	Boost Target	Overweight	$125.00 ➝ $140.00	High
5/28/2021	Mizuho	Boost Target	Buy	$90.00 ➝ $92.00	Low
5/18/2021	Morgan Stanley	Lower Target	Equal Weight	$76.00 ➝ $69.00	High
5/12/2021	SVB Leerink	Lower Target	Outperform	$115.00 ➝ $105.00	Medium
5/11/2021	Mizuho	Lower Target	Buy	$98.00 ➝ $90.00	Medium
5/3/2021	Mizuho	Lower Target	Buy	$103.00 ➝ $98.00	N/A
4/26/2021	Mizuho	Lower Target	Buy	$103.00 ➝ $98.00	Low
4/19/2021	Morgan Stanley	Boost Target	Equal Weight	$73.00 ➝ $76.00	Medium
3/11/2021	UBS Group	Initiated Coverage	Buy	$108.00	High
3/2/2021	Mizuho	Boost Target	Buy	$93.00 ➝ $103.00	High
3/1/2021	Piper Sandler	Boost Target	Overweight	$90.00 ➝ $110.00	Low
2/5/2021	William Blair	Reiterated Rating	Buy		Medium
1/19/2021	Mizuho	Lower Target		$100.00 ➝ $93.00	High
1/19/2021	HC Wainwright	Lower Target	Buy	$121.00 ➝ $111.00	High
12/29/2020	Cantor Fitzgerald	Boost Target	Overweight	$109.00 ➝ $115.00	N/A
12/16/2020	Morgan Stanley	Boost Target	Equal Weight	$63.00 ➝ $73.00	Medium
12/15/2020	HC Wainwright	Initiated Coverage	Buy	$121.00	Medium
12/7/2020	SVB Leerink	Boost Target	Outperform	$85.00 ➝ $120.00	Medium
11/13/2020	Mizuho	Boost Target	Buy	$82.00 ➝ $100.00	Low
10/13/2020	Wedbush	Boost Target	Outperform	$96.00 ➝ $99.00	Low
10/13/2020	Morgan Stanley	Boost Target	Equal Weight	$57.00 ➝ $63.00	Low
8/24/2020	Morgan Stanley	Lower Target	Equal Weight	$60.00 ➝ $57.00	High
8/10/2020	William Blair	Reiterated Rating	Buy		High
7/15/2020	Morgan Stanley	Boost Target	Equal Weight	$50.00 ➝ $60.00	Low
6/26/2020	Mizuho	Initiated Coverage	Buy	$85.00	Low
6/23/2020	Cantor Fitzgerald	Boost Target	Overweight	$82.00 ➝ $109.00	Low
6/18/2020	Wedbush	Boost Target	Outperform	$74.00 ➝ $94.00	Low
6/15/2020	Cowen	Boost Target	Outperform	$60.00 ➝ $80.00	High
6/9/2020	Mizuho	Reiterated Rating	Buy	$53.00 ➝ $85.00	High
5/20/2020	Mizuho	Reiterated Rating	Buy	$53.00	High
5/11/2020	Cantor Fitzgerald	Boost Target	Overweight	$75.00 ➝ $82.00	Low
5/11/2020	Morgan Stanley	Boost Target	Equal Weight	$46.00 ➝ $50.00	High
5/8/2020	Oppenheimer	Reiterated Rating	Hold	$41.00	Low
4/17/2020	Cowen	Initiated Coverage	Outperform	$45.00	High
4/15/2020	Morgan Stanley	Lower Target	Equal Weight	$49.00 ➝ $46.00	Medium
3/31/2020	Oppenheimer	Lower Target	Market Perform	$48.00 ➝ $37.00	Low
3/13/2020	Wedbush	Boost Target	Outperform	$73.00 ➝ $78.00	High
2/23/2020	Mizuho	Reiterated Rating	Buy	$58.00	High
2/10/2020	The Goldman Sachs Group	Lower Target	Buy	$89.00 ➝ $76.00	Medium
2/10/2020	Oppenheimer	Downgrade	Outperform ➝ Market Perform	$67.00 ➝ $51.00	High
2/5/2020	Mizuho	Initiated Coverage	Buy	$62.00	Low
1/29/2020	Wedbush	Reiterated Rating	Buy	$75.00	High
12/23/2019	Piper Sandler Companies	Reiterated Rating	Buy	$100.00	Medium
12/17/2019	Piper Sandler Companies	Reiterated Rating	Buy	$100.00	Medium
12/12/2019	Wedbush	Initiated Coverage	Outperform	$75.00	Low
12/10/2019	William Blair	Reiterated Rating	Buy		Low
12/6/2019	SVB Leerink	Boost Target	Positive ➝ Outperform	$62.00 ➝ $64.00	Medium
11/27/2019	Wedbush	Initiated Coverage	Outperform	$75.00	N/A
11/21/2019	Wedbush	Initiated Coverage	Outperform	$75.00	High
10/28/2019	Cantor Fitzgerald	Boost Target	Overweight	$87.00 ➝ $92.00	High
10/9/2019	Oppenheimer	Set Target	Buy	$67.00	N/A
9/17/2019	William Blair	Reiterated Rating	Buy		Low
9/4/2019	Cantor Fitzgerald	Set Target	Buy	$87.00	Low
9/4/2019	The Goldman Sachs Group	Set Target	Buy	$89.00	Low
8/9/2019	Morgan Stanley	Set Target	Hold	$50.00	High
7/22/2019	Morgan Stanley	Lower Target	Equal Weight	$55.00 ➝ $51.00	High
7/15/2019	Morgan Stanley	Set Target	Hold	$55.00	Low
6/19/2019	Oppenheimer	Set Target	Buy	$68.00	Medium
5/31/2019	Barclays	Reiterated Rating	Hold	$55.00	Low
5/14/2019	Morgan Stanley	Boost Target	Equal Weight	$55.00 ➝ $57.00	High
5/8/2019	Needham & Company LLC	Boost Target	Buy	$70.00	High
5/8/2019	Piper Sandler Companies	Boost Target	Overweight	$75.00 ➝ $100.00	High
5/6/2019	The Goldman Sachs Group	Initiated Coverage	Buy	$92.00 ➝ $92.00	High

(Data available from 4/28/2019 forward)

News Sentiment Rating

0.73 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

8 very positive mentions
3 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

10/1/2023

6 very positive mentions
5 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

10/31/2023

4 very positive mentions
3 positive mentions
3 negative mentions
0 very negative mentions

Mentions as of

11/30/2023

8 very positive mentions
10 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

12/30/2023

5 very positive mentions
2 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

1/29/2024

11 very positive mentions
13 positive mentions
0 negative mentions
1 very negative mentions

Mentions as of

2/28/2024

19 very positive mentions
20 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

3/29/2024

18 very positive mentions
22 positive mentions
2 negative mentions
0 very negative mentions

Mentions as of

4/28/2024

Current Sentiment

Recent Stories by Sentiment

Very Negative

No very negative mentions tracked during this time.

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.

Today's Range

Now: $38.97

$37.75

$39.28

50 Day Range

MA: $50.90

$38.32

$59.74

52 Week Range

Now: $38.97

$12.35

$62.21

Volume

948,357 shs

Average Volume

1,391,304 shs

Market Capitalization

$3.44 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.18

Frequently Asked Questions

What sell-side analysts currently cover shares of Biohaven?: The following Wall Street sell-side analysts have issued stock ratings on Biohaven in the last twelve months: BTIG Research, Cantor Fitzgerald, HC Wainwright, JPMorgan Chase & Co., Piper Sandler, Robert W. Baird, Royal Bank of Canada, TD Cowen, and UBS Group AG.
View the latest analyst ratings for BHVN.
What is the current price target for Biohaven?: 8 Wall Street analysts have set twelve-month price targets for Biohaven in the last year. Their average twelve-month price target is $52.13, suggesting a possible upside of 33.8%. HC Wainwright has the highest price target set, predicting BHVN will reach $63.00 in the next twelve months. BTIG Research has the lowest price target set, forecasting a price of $28.00 for Biohaven in the next year.
View the latest price targets for BHVN.
What is the current consensus analyst rating for Biohaven?: Biohaven currently has 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe BHVN will outperform the market and that investors should add to their positions of Biohaven.
View the latest ratings for BHVN.
What other companies compete with Biohaven?: Other companies that are similar to Biohaven include HUTCHMED, Amicus Therapeutics, Bausch Health Companies, Xenon Pharmaceuticals and Crinetics Pharmaceuticals. Learn More about companies similar to Biohaven.
How do I contact Biohaven's investor relations team?: Biohaven's physical mailing address is 215 CHURCH STREET, NEW HAVEN CT, 06510. The company's listed phone number is 203-404-0410 and its investor relations email address is [email protected]. The official website for Biohaven is www.biohavenpharma.com. Learn More about contacing Biohaven investor relations.

Biohaven - BHVN Stock Price Target and Predictions

Analyst Price Target for BHVN

Current Consensus is Buy

Past Monthly Recommendations

Latest Recommendations

News Sentiment Rating

0.73 (Buy)

News Sentiment Over Time

Current Sentiment

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Biohaven?

What is the current price target for Biohaven?

What is the current consensus analyst rating for Biohaven?

What other companies compete with Biohaven?

How do I contact Biohaven's investor relations team?